Genes of the TCF3 pathway (TCF3, ID3, CCND3) constitute targets of BL-specific second mutation hits in around 90% of BL, following MYC-translocation [49] rendering BL differently from MYC-translocated DLBCL. This evidence concerns the gene TCF3 and diffuse large B-cell lymphoma.